<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RANITIDINE - ranitidine hydrochloride syrup </strong><br>Heritage Pharmaceuticals Inc.<br></p></div>
<h1>
<span class="Bold">Ranitidine Syrup (Ranitidine Oral Solution, USP)</span><br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1><span class="Bold">DESCRIPTION
</span></h1>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The active ingredient in Ranitidine Syrup (Ranitidine Oral Solution, USP) is ranitidine hydrochloride (HCl), USP, a histamine H<span class="Sub">2</span>-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-1,1- ethenediamine, HCl. It has the following structure:</p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"><img alt="Structure.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd7a6355-0341-4bce-a942-2a8bba3fb669&amp;name=6bf5f8d4-figure-01.jpg"></p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The molecular formula is C<span class="Sub">13</span>H<span class="Sub">22</span>N<span class="Sub">4</span>O<span class="Sub">3</span>S•HCl, representing a molecular weight of 350.87.</p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Ranitidine HCl is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow crystalline powder that is very soluble in water and sparingly soluble in alcohol.</p></dd>
<dt></dt>
<dd><p class="First"> Each mL of Ranitidine oral solution USP contains 16.8 mg of ranitidine HCl equivalent to 15 mg of ranitidine. Ranitidine oral solution USP also contains the inactive ingredients 7.5% alcohol, butylparaben, dibasic sodium phosphate, hypromellose, monobasic potassium phosphate, natural &amp; artificial mint flavor, propylparaben, purified water, saccharin sodium, sodium chloride, and sorbitol solution.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY
</span></h1>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Ranitidine is a competitive, reversible inhibitor of the action of histamine at the histamine H<span class="Sub">2</span>-receptors, including receptors on the gastric cells. Ranitidine does not lower serum Ca++ in hypercalcemic states. Ranitidine is not an anticholinergic agent.</p></dd>
</dl>  </dd>
</dl>
<div class="Section" data-sectionCode="43682-4">
<a name="b34ce51a-1d7b-4222-bf4b-abf3a896fb87"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold Italics">Pharmacokinetics
</span></h2>
<div class="Section">
<a name="section-2.1.1"></a><p></p>
<h3><span class="Bold">Absorption
</span></h3>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Ranitidine is 50% absorbed after oral administration, compared to an intravenous (IV) injection with mean peak levels of 440 to 545 ng/mL occurring 2 to 3 hours after a 150-mg dose. The oral solution formulation is bioequivalent to the tablets. Absorption is not significantly impaired by the administration of food or antacids. Propantheline slightly delays and increases peak blood levels of ranitidine, probably by delaying gastric emptying and transit time. In one study, simultaneous administration of high-potency antacid (150 mmol) in fasting subjects has been reported to decrease the absorption of ranitidine.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-2.1.2"></a><p></p>
<h3><span class="Bold">Distribution
</span></h3>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The volume of distribution is about 1.4 L/kg. Serum protein binding averages 15%.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-2.1.3"></a><p></p>
<h3><span class="Bold">Metabolism
</span></h3>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> In humans, the N-oxide is the principal metabolite in the urine; however, this amounts to &lt;4% of the dose. Other metabolites are the S-oxide (1%) and the desmethyl ranitidine (1%). The remainder of the administered dose is found in the stool. Studies in patients with hepatic dysfunction (compensated cirrhosis) indicate that there are minor, but clinically insignificant, alterations in ranitidine half-life, distribution, clearance, and bioavailability.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-2.1.4"></a><p></p>
<h3><span class="Bold">Excretion
</span></h3>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The principal route of excretion is the urine, with approximately 30% of the orally administered dose collected in the urine as unchanged drug in 24 hours. Renal clearance is about 410 mL/min, indicating active tubular excretion. The elimination half-life is 2.5 to 3 hours. Four patients with clinically significant renal function impairment (creatinine clearance 25 to 35 mL/min) administered 50 mg of ranitidine intravenously had an average plasma half-life of 4.8 hours, a ranitidine clearance of 29 mL/min, and a volume of distribution of 1.76  L/kg. In general, these parameters appear to be altered in proportion to creatinine clearance (see <a href="#b825dd64-7cf2-4221-93c4-2dc8cc6b17c8">DOSAGE AND ADMINISTRATION</a>).</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="b811b210-4b96-4ff1-ba7a-f1504af17ec2"></a><a name="section-2.1.5"></a><p></p>
<h3><span class="Bold">Geriatrics
</span></h3>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The plasma half-life is prolonged and total clearance is reduced in the elderly population due to a decrease in renal function. The elimination half-life is 3 to 4 hours. Peak levels average 526 ng/mL following a 150-mg twice daily dose and occur in about 3 hours (see <a href="#b4cfbfee-a3e2-4091-9a4c-9c41ce04391a">PRECAUTIONS: Geriatric Use</a> and <a href="#b6cc961e-ecd6-404b-9e62-cc5c9f47b040">DOSAGE AND ADMINISTRATION: Dosage Adjustment for Patients</a><a href="#b855e588-bbc3-47d1-a123-130778c5e956">With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a>).</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="bd54b83d-5e81-4ae9-b979-3d3d363d768b"></a><a name="section-2.1.6"></a><p></p>
<h3><span class="Bold">Pediatrics
</span></h3>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> There are no significant differences in the pharmacokinetic parameter values for ranitidine in pediatric patients (from 1 month up to 16 years of age) and healthy adults when correction is made for body weight. The average bioavailability of ranitidine given orally to pediatric patients is 48% which is comparable to the bioavailability of ranitidine in the adult population. All other pharmacokinetic parameter values (t<span class="Sub">1/2</span>, Vd, and CL) are similar to those observed with intravenous ranitidine use in pediatric patients. Estimates of Cmax and Tmax are displayed in Table 1.</p></dd>
</dl>  </dd>
</dl>
<table frame="void" width="650">
<caption><span> Table 1. Ranitidine Pharmacokinetics in Pediatric Patients Following Oral Dosing </span></caption>
<thead><tr class="First Last">
<td class="Toprule" align="left" valign="top"> Population<br>(age)</td>
<td class="Toprule" align="left" valign="top"> n</td>
<td class="Toprule" align="left" valign="top"> Dosage Form (dose)</td>
<td class="Toprule" align="left" valign="top"> Cmax<br>(ng/mL)</td>
<td class="Toprule" align="left" valign="top"> Tmax<br>(hours)</td>
</tr></thead>
<tbody>
<tr class="First">
<td align="left" valign="top">Gastric or <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span><br>(3.5 to 16 years)</td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">Tablets<br>(1 to 2 mg/kg)</td>
<td align="center" valign="top">54 to 492</td>
<td align="center" valign="top">2.0</td>
</tr>
<tr>
<td align="left" valign="top">Otherwise healthy requiring ranitidine<br>(0.7 to 14 years, Single dose)</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">Oral Solution<br>(2 mg/kg)</td>
<td align="center" valign="top">244</td>
<td align="center" valign="top">1.61</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Otherwise healthy requiring ranitidine<br>(0.7 to 14 years, Multiple dose)</td>
<td class="Botrule" align="center" valign="top">10</td>
<td class="Botrule" align="center" valign="top">Oral Solution<br>(2 mg/kg)</td>
<td class="Botrule" align="center" valign="top">320</td>
<td class="Botrule" align="center" valign="top">1.66</td>
</tr>
</tbody>
</table>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Plasma clearance measured in 2 neonatal patients (less than 1 month of age) was considerably lower (3 mL/min/kg) than children or adults and is likely due to reduced renal function observed in this population (see <a href="#b205740b-dd5a-4d81-8691-ef33db4587de">PRECAUTIONS: Pediatric Use</a> and <a href="#b2a0fc62-64f1-4ee9-8ef7-b442553bebdf">DOSAGE AND ADMINISTRATION: Pediatric Use</a>).</p></dd>
</dl>  </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-2.2"></a><p></p>
<h2><span class="Bold Italics">Pharmacodynamics
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Serum concentrations necessary to inhibit 50% of stimulated gastric acid secretion are estimated to be 36 to 94 ng/mL. Following a single oral dose of 150 mg, serum concentrations of ranitidine are in this range up to 12 hours. However, blood levels bear no consistent relationship to dose or degree of acid inhibition.</p></dd>
</dl>  </dd>
</dl>
<div class="Section">
<a name="section-2.2.1"></a><p></p>
<h3><span class="Bold">Antisecretory Activity
</span></h3>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> 1. Effects on Acid Secretion</p></dd>
<dt></dt>
<dd><p class="First"> Ranitidine inhibits both daytime and nocturnal basal gastric acid secretions as well as gastric acid secretion stimulated by food, betazole, and pentagastrin, as shown in Table 2.</p></dd>
</dl>  </dd>
</dl>
<table frame="void" width="590">
<caption><span>  Table 2. Effect of Oral Ranitidine on Gastric Acid Secretion</span></caption>
<thead>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"></td>
<td class="Botrule Toprule" align="left" valign="top"><span class="Bold"> Time After Dose, hours</span></td>
<td class="Botrule Toprule" align="left" colspan="4" valign="top">  <span class="Bold">% Inhibition of Gastric Acid Output by Dose, mg</span>  </td>
</tr>
<tr class="Last">
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"> 75-80</td>
<td class="Toprule" align="left" valign="top"> 100</td>
<td class="Toprule" align="left" valign="top"> 150</td>
<td class="Toprule" align="left" valign="top"> 200</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="center" valign="top">Basal</td>
<td align="center" valign="top">Up to 4</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">99</td>
<td align="center" valign="top">95</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">Nocturnal</td>
<td align="center" valign="top">Up to 13</td>
<td align="center" valign="top">95</td>
<td align="center" valign="top">96</td>
<td align="center" valign="top">92</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">Betazole</td>
<td align="center" valign="top">Up to 3</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">97</td>
<td align="center" valign="top">99</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">Pentagastrin</td>
<td align="center" valign="top">Up to 5</td>
<td align="center" valign="top">58</td>
<td align="center" valign="top">72</td>
<td align="center" valign="top">72</td>
<td align="center" valign="top">80</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">Meal</td>
<td class="Botrule" align="center" valign="top">Up to 3</td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">73</td>
<td class="Botrule" align="center" valign="top">79</td>
<td class="Botrule" align="center" valign="top">95</td>
</tr>
</tbody>
</table>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> It appears that basal-, nocturnal-, and betazole-stimulated secretions are most sensitive to inhibition by ranitidine, responding almost completely to doses of 100 mg or less, while pentagastrin- and food-stimulated secretions are more difficult to suppress.</p></dd>
<dt></dt>
<dd><p class="First"> 2. Effects on Other Gastrointestinal Secretions</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-2.2.2"></a><p></p>
<h3><span class="Italics">Pepsin
</span></h3>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Oral ranitidine does not affect pepsin secretion. Total pepsin output is reduced in proportion to the decrease in volume of gastric juice.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-2.2.3"></a><p></p>
<h3><span class="Italics">Intrinsic Factor
</span></h3>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Oral ranitidine has no significant effect on pentagastrin-stimulated intrinsic factor secretion.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-2.2.4"></a><p></p>
<h3><span class="Italics">Serum Gastrin
</span></h3>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Ranitidine has little or no effect on fasting or postprandial serum gastrin.</p></dd>
<dt></dt>
<dd><p class="First"> Other Pharmacologic Actions</p></dd>
</dl>  </dd>
</dl>
<ol class="Arabic">
<li>Gastric bacterial flora—increase in nitrate-reducing organisms, significance not known.</li>
<li>Prolactin levels—no effect in recommended oral or IV dosage, but small, transient, dose-related increases in serum prolactin have been reported after IV bolus injections of 100 mg or more.</li>
<li>Other pituitary hormones—no effect on serum gonadotropins, TSH, or GH. Possible impairment of vasopressin release.</li>
<li>No change in cortisol, aldosterone, androgen, or estrogen levels.</li>
<li>No antiandrogenic action.</li>
<li>No effect on count, motility, or morphology of sperm.</li>
</ol>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Pediatrics</p></dd>
<dt></dt>
<dd><p class="First"> Oral doses of 6 to 10 mg/kg/day in 2 or 3 divided doses maintain gastric pH&gt;4 throughout most of the dosing interval.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="b082a525-848d-4511-9d4e-0a33b3f0442c"></a><a name="section-2.2.5"></a><p></p>
<h3><span class="Bold">Clinical Trials
</span></h3>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></p></dd>
<dt></dt>
<dd><p class="First"> In a multicenter, double-blind, controlled, US study of endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>, earlier healing was seen in the patients treated with ranitidine as shown in Table 3.</p></dd>
</dl>  </dd>
</dl>
<table frame="void" width="557">
<caption><span> Table 3. <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Patient Healing Rates</span></caption>
<thead>
<tr class="First">
<td align="left" rowspan="2" valign="top"></td>
<td align="left" colspan="2" valign="top"> Ranitidine*</td>
<td align="left" colspan="2" valign="top"> Placebo*</td>
</tr>
<tr class="Last">
<td align="left" valign="top"> Number Entered</td>
<td align="left" valign="top"> Healed/ Evaluable</td>
<td align="left" valign="top"> Number Entered</td>
<td align="left" valign="top"> Healed/ Evaluable</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="5" valign="top"> *All patients were permitted antacids as needed for relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. </td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"> †P&lt;0.0001. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top">Outpatients</td>
<td class="Botrule" align="left" rowspan="3" valign="top">195</td>
<td align="left" rowspan="2" valign="top">69/182<br> (38%)†</td>
<td class="Botrule" align="left" rowspan="3" valign="top">188</td>
<td align="left" rowspan="2" valign="top">31/164<br>(19%)</td>
</tr>
<tr><td align="left" valign="top">Week 2</td></tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Week 4</td>
<td class="Botrule" align="left" valign="top">137/187<br>(73%)†</td>
<td class="Botrule" align="left" valign="top">76/168<br>(45%)</td>
</tr>
</tbody>
</table>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> In these studies, patients treated with ranitidine reported a reduction in both daytime and nocturnal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and they also consumed less antacid than the placebo-treated patients.</p></dd>
</dl>  </dd>
</dl>
<table frame="void" width="339">
<caption><span> Table 4. Mean Daily Doses of Antacid</span></caption>
<thead><tr class="First Last">
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Healed</td>
<td class="Toprule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Not Healed</td>
</tr></thead>
<tbody>
<tr class="First">
<td align="left" valign="top">Ranitidine </td>
<td align="center" valign="top">0.06</td>
<td align="center" valign="top">0.71</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Placebo</td>
<td class="Botrule" align="center" valign="top">0.71</td>
<td class="Botrule" align="center" valign="top">1.43</td>
</tr>
</tbody>
</table>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Foreign studies have shown that patients heal equally well with 150 mg twice daily and 300 mg at bedtime (85% versus 84%, respectively) during a usual 4-week course of therapy. If patients require extended therapy of 8 weeks, the healing rate may be higher for 150 mg twice daily as compared to 300 mg at bedtime (92% versus 87%, respectively).</p></dd>
<dt></dt>
<dd><p class="First"> Studies have been limited to short-term treatment of acute <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>. Patients whose <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> healed during therapy had recurrences of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> at the usual rates.</p></dd>
<dt></dt>
<dd><p class="First"> Maintenance Therapy in <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></p></dd>
<dt></dt>
<dd><p class="First"> Ranitidine has been found to be effective as maintenance therapy for patients following healing of acute <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>. In 2 independent, double-blind, multicenter, controlled trials, the number of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> observed was significantly less in patients treated with ranitidine (150 mg at bedtime) than in patients treated with placebo over a 12-month period.</p></dd>
</dl>  </dd>
</dl>
<table frame="void" width="568"><tbody class="Headless">
<tr class="First"><td class="Botrule" align="center" colspan="6" valign="top"><span class="Bold">Table 5. <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Prevalence</span></td></tr>
<tr><td class="Toprule" align="center" colspan="6" valign="top">Double-Blind, Multicenter, Placebo-Controlled Trials</td></tr>
<tr>
<td align="left" rowspan="2" valign="top">Multicenter Trial</td>
<td align="center" rowspan="2" valign="top">Drug</td>
<td align="center" colspan="3" valign="top"><span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Prevalence</td>
<td align="center" rowspan="2" valign="top">No. of Patients</td>
</tr>
<tr>
<td align="center" valign="top">0-4 Months</td>
<td align="center" valign="top">0-8 Months</td>
<td align="center" valign="top">0-12 Months</td>
</tr>
<tr>
<td align="left" rowspan="2" valign="top">USA</td>
<td align="center" valign="top">RAN</td>
<td align="center" valign="top">20%*</td>
<td align="center" valign="top">24%*</td>
<td align="center" valign="top">35%*</td>
<td align="center" valign="top">138</td>
</tr>
<tr>
<td align="center" valign="top">PLC</td>
<td align="center" valign="top">44%</td>
<td align="center" valign="top">54%</td>
<td align="center" valign="top">59%</td>
<td align="center" valign="top">139</td>
</tr>
<tr>
<td class="Botrule" align="left" rowspan="2" valign="top">Foreign</td>
<td align="center" valign="top">RAN</td>
<td align="center" valign="top">12%*</td>
<td align="center" valign="top">21%*</td>
<td align="center" valign="top">28%*</td>
<td align="center" valign="top">174</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top">PLC</td>
<td class="Botrule" align="center" valign="top">56%</td>
<td class="Botrule" align="center" valign="top">64%</td>
<td class="Botrule" align="center" valign="top">68%</td>
<td class="Botrule" align="center" valign="top">165</td>
</tr>
<tr><td class="Toprule" align="left" colspan="6" valign="middle">% = Life table estimate.</td></tr>
<tr><td align="left" colspan="6" valign="middle">* = P&lt;0.05 (Ranitidine versus comparator).</td></tr>
<tr><td align="left" colspan="6" valign="middle">RAN = ranitidine.</td></tr>
<tr class="Last"><td align="left" colspan="6" valign="middle">PLC = placebo.</td></tr>
</tbody></table>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> As with other H<span class="Sub">2</span>-antagonists, the factors responsible for the significant reduction in the prevalence of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> include prevention of recurrence of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, more rapid healing of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> that may occur during maintenance therapy, or both.</p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></p></dd>
<dt></dt>
<dd><p class="First"> In a multicenter, double-blind, controlled, US study of endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>, earlier healing was seen in the patients treated with ranitidine as shown in Table 6.</p></dd>
</dl>  </dd>
</dl>
<table frame="void" width="549">
<caption><span> Table 6. <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> Patient Healing Rates</span></caption>
<thead>
<tr class="First">
<td class="Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Toprule" align="left" colspan="2" valign="top"> Ranitidine*</td>
<td class="Toprule" align="left" colspan="2" valign="top"> Placebo*</td>
</tr>
<tr class="Last">
<td align="left" valign="top"> Number Entered</td>
<td class="Botrule" align="left" valign="top"> Healed/ Evaluable</td>
<td align="left" valign="top"> Number Entered</td>
<td class="Botrule" align="left" valign="top"> Healed/ Evaluable</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="5" valign="top"> *All patients were permitted antacids as needed for relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.  </td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"> †P = 0.009.  </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top">Outpatients</td>
<td class="Botrule" align="left" rowspan="3" valign="top">92</td>
<td class="Toprule" align="left" valign="top"></td>
<td class="Botrule" align="left" rowspan="3" valign="top">94</td>
<td class="Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Week 2</td>
<td align="left" valign="top">16/83<br>(19%)</td>
<td align="left" valign="top">10/83<br> (12%)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Week 6</td>
<td class="Botrule" align="left" valign="top">50/73<br>(68%)†</td>
<td class="Botrule" align="left" valign="top">35/69<br>(51%)</td>
</tr>
</tbody>
</table>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> In this multicenter trial, significantly more patients treated with ranitidine became <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> free during therapy.</p></dd>
<dt></dt>
<dd><p class="First"> Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcers</span></p></dd>
<dt></dt>
<dd><p class="First"> In 2 multicenter, double-blind, randomized, placebo-controlled, 12-month trials conducted in patients whose <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> had been previously healed, ranitidine 150 mg at bedtime was significantly more effective than placebo in maintaining healing of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>.</p></dd>
<dt></dt>
<dd><p class="First"> Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome)</p></dd>
<dt></dt>
<dd><p class="First"> Ranitidine inhibits gastric acid secretion and reduces occurrence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in patients with pathological hypersecretion associated with Zollinger-Ellison syndrome, <span class="product-label-link" type="condition" conceptid="4246284" conceptname="Systemic mast cell disease">systemic mastocytosis</span>, and other pathological hypersecretory conditions (e.g., postoperative, "short-gut" syndrome, idiopathic). Use of ranitidine was followed by healing of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in 8 of 19 (42%) patients who were intractable to previous therapy.</p></dd>
<dt></dt>
<dd><p class="First"> <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</p></dd>
<dt></dt>
<dd><p class="First"> In 2 multicenter, double-blind, placebo-controlled, 6-week trials performed in the United States and Europe, ranitidine 150 mg twice daily was more effective than placebo for the relief of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and other symptoms associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. Ranitidine-treated patients consumed significantly less antacid than did placebo-treated patients.</p></dd>
<dt></dt>
<dd><p class="First"> The US trial indicated that ranitidine 150 mg twice daily significantly reduced the frequency of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> attacks and severity of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> within 1 to 2 weeks after starting therapy. The improvement was maintained throughout the 6-week trial period. Moreover, patient response rates demonstrated that the effect on <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> extends through both the day and night time periods.</p></dd>
<dt></dt>
<dd><p class="First"> In 2 additional US multicenter, double-blind, placebo-controlled, 2-week trials, ranitidine 150 mg twice daily was shown to provide relief of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> within 24 hours of initiating therapy and a reduction in the frequency of severity of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>.</p></dd>
<dt></dt>
<dd><p class="First"> <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></p></dd>
<dt></dt>
<dd><p class="First"> In 2 multicenter, double-blind, randomized, placebo-controlled, 12-week trials performed in the United States, ranitidine 150 mg 4 times daily was significantly more effective than placebo in healing endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> and in relieving associated <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>. The <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> healing rates were as follows:</p></dd>
</dl>  </dd>
</dl>
<table frame="void" width="482">
<caption><span> Table 7. <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Patient Healing Rates</span></caption>
<thead>
<tr class="First">
<td class="Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Toprule" align="center" colspan="2" valign="top"> Healed/Evaluable</td>
</tr>
<tr class="Last">
<td align="center" valign="top"> Placebo* <br>n = 229</td>
<td align="center" valign="top"> Ranitidine <br>150 mg 4 times daily*<br>n = 215</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"> *All patients were permitted antacids as needed for relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.<br>
</td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"> †P&lt;0.001 versus placebo.<br>
</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top">Week 4</td>
<td align="center" valign="top">43/198 (22%)</td>
<td align="center" valign="top">96/206 (47%)†</td>
</tr>
<tr>
<td align="left" valign="top">Week 8</td>
<td align="center" valign="top">63/176 (36%)</td>
<td align="center" valign="top">142/200 (71%)†</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Week 12</td>
<td align="center" valign="top">92/159 (58%)</td>
<td align="center" valign="top">162/192 (84%)†</td>
</tr>
</tbody>
</table>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> No additional benefit in healing of <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> or in relief of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> was seen with a ranitidine dose of 300 mg 4 times daily.</p></dd>
<dt></dt>
<dd><p class="First"> Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></p></dd>
<dt></dt>
<dd><p class="First"> In 2 multicenter, double-blind, randomized, placebo-controlled, 48-week trials conducted in patients whose <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> had been previously healed, ranitidine 150 mg twice daily was significantly more effective than placebo in maintaining healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>.</p></dd>
</dl>  </dd>
</dl>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE
</span></h1>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Ranitidine oral solution USP is indicated in:</p></dd>
</dl>  </dd>
</dl>
<ol class="Arabic">
<li>Short-term treatment of active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> for periods of more than 8 weeks.</li>
<li>Maintenance therapy for <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> patients at reduced dosage after healing of acute <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year.</li>
<li>The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and <span class="product-label-link" type="condition" conceptid="4246284" conceptname="Systemic mast cell disease">systemic mastocytosis</span>).</li>
<li>Short-term treatment of active, benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> for periods of more than 6 weeks.</li>
<li>Maintenance therapy for <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> patients at reduced dosage after healing of acute <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>. Placebo-controlled studies have been carried out for 1 year.</li>
<li>Treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily.</li>
<li>Treatment of endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>. Symptomatic relief of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily.</li>
<li>Maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>. Placebo-controlled trials have been carried out for 48 weeks.</li>
</ol>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Concomitant antacids should be given as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief to patients with active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>; active, benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>; hypersecretory states; <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>; and <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Ranitidine oral solution USP is contraindicated for patients known to have <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or any of the ingredients (see <a href="#bc33c573-894a-4799-8236-2f639a069f01">PRECAUTIONS</a>).</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="bc33c573-894a-4799-8236-2f639a069f01"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">PRECAUTIONS
</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-5.1"></a><p></p>
<h2><span class="Bold Italics">General:
</span></h2>
<ol class="Arabic">
<li>Symptomatic response to therapy with ranitidine does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>.</li>
<li>Since ranitidine is excreted primarily by the kidney, dosage should be adjusted in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (see <a href="#bfee2f1d-b920-415c-8876-b11b95d61ccb">DOSAGE AND ADMINISTRATION</a>). Caution should be observed in patients with hepatic dysfunction since ranitidine is metabolized in the liver.</li>
<li>Rare reports suggest that ranitidine may precipitate acute porphyric attacks in patients with acute <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>. Ranitidine should therefore be avoided in patients with a history of acute <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-5.2"></a><p></p>
<h2><span class="Bold Italics">Laboratory Tests
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> False-positive tests for urine protein with MULTISTIX<span class="Sup">®</span> may occur during ranitidine therapy, and therefore testing with sulfosalicylic acid is recommended.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-5.3"></a><p></p>
<h2><span class="Bold Italics">Drug Interactions
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Ranitidine has been reported to affect the bioavailability of other drugs through several different mechanisms such as competition for renal tubular secretion, alteration of gastric pH, and inhibition of cytochrome P450 enzymes.</p></dd>
<dt></dt>
<dd><p class="First"> Procainamide:Ranitidine, a substrate of the renal organic cation transport system, may affect the clearance of other drugs eliminated by this route. High doses of ranitidine (e.g., such as those used in the treatment of Zollinger-Ellison syndrome) have been shown to reduce the renal excretion of procainamide and N-acetylprocainamide resulting in increased plasma levels of these drugs. Although this interaction is unlikely to be clinically relevant at usual ranitidine doses, it may be prudent to monitor for procainamide toxicity when administered with oral ranitidine at a dose exceeding 300 mg per day.</p></dd>
<dt></dt>
<dd><p class="First"> Warfarin:There have been reports of altered <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time among patients on concomitant warfarin and ranitidine therapy. Due to the narrow therapeutic index, close monitoring of increased or decreased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time is recommended during concurrent treatment with ranitidine.</p></dd>
<dt></dt>
<dd><p class="First"> Ranitidine may alter the absorption of drugs in which gastric pH is an important determinant of bioavailability. This can result in either an increase in absorption (e.g., triazolam, midazolam, glipizide) or a decrease in absorption (e.g., ketoconazole, atazanavir, delavirdine, gefitinib). Appropriate clinical monitoring is recommended.</p></dd>
<dt></dt>
<dd><p class="First"> Atazanavir:Atazanavir absorption may be impaired based on known interactions with other agents that increase gastric pH. Use with caution. See atazanavir label for specific recommendations.</p></dd>
<dt></dt>
<dd><p class="First"> Delavirdine:Delavirdine absorption may be impaired based on known interactions with other agents that increase gastric pH. Chronic use of H2-receptor antagonists with delavirdine is not recommended.</p></dd>
<dt></dt>
<dd><p class="First"> Gefitinib: Gefitinib exposure was reduced by 44% with the coadministration of ranitidine and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (dosed to maintain gastric pH above 5.0). Use with caution.</p></dd>
<dt></dt>
<dd><p class="First"> Glipizide:In diabetic patients, glipizide exposure was increased by 34% following a single 150-mg dose of oral ranitidine. Use appropriate clinical monitoring when initiating or discontinuing ranitidine.</p></dd>
<dt></dt>
<dd><p class="First"> Ketoconazole:Oral ketoconazole exposure was reduced by up to 95% when oral ranitidine was coadministered in a regimen to maintain a gastric pH of 6 or above. The degree of interaction with usual dose of ranitidine (150 mg twice daily) is unknown.</p></dd>
<dt></dt>
<dd><p class="First"> Midazolam:Oral midazolam exposure in 5 healthy volunteers was increased by up to 65% when administered with oral ranitidine at a dose of 150 mg twice daily. However, in another interaction study in 8 volunteers receiving IV midazolam, a 300 mg oral dose of ranitidine increased midazolam exposure by about 9%. Monitor patients for excessive or prolonged sedation when ranitidine is coadministered with oral midazolam.</p></dd>
<dt></dt>
<dd><p class="First"> Triazolam:Triazolam exposure in healthy volunteers was increased by approximately 30% when administered with oral ranitidine at a dose of 150 mg twice daily. Monitor patients for excessive or prolonged sedation.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-5.4"></a><p></p>
<h2><span class="Bold Italics">Carcinogenesis, Mutagenesis, Impairment of Fertility
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> There was no indication of tumorigenic or carcinogenic effects in life-span studies in mice and rats at dosages up to 2,000 mg/kg/day.</p></dd>
<dt></dt>
<dd><p class="First"> Ranitidine was not mutagenic in standard bacterial tests (<span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>, Escherichia coli) for mutagenicity at concentrations up to the maximum recommended for these assays.</p></dd>
<dt></dt>
<dd><p class="First"> In a dominant lethal assay, a single oral dose of 1,000 mg/kg to male rats was without effect on the outcome of 2 matings per week for the next 9 weeks.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-5.5"></a><p></p>
<h2><span class="Bold Italics">Pregnancy
</span></h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-5.5.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects:
</span></h3>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Pregnancy Category B. Reproduction studies have been performed in rats and rabbits at doses up to 160 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to ranitidine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p></dd>
</dl>  </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-5.6"></a><p></p>
<h2><span class="Bold Italics">Nursing Mothers
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Ranitidine is secreted in human milk. Caution should be exercised when ranitidine is administered to a nursing mother.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="b205740b-dd5a-4d81-8691-ef33db4587de"></a><a name="section-5.7"></a><p></p>
<h2><span class="Bold Italics">Pediatric Use
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The safety and effectiveness of ranitidine have been established in the age-group of 1 month to 16 years for the treatment of duodenal and <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> and <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>, and the maintenance of healed duodenal and <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>. Use of ranitidine in this age-group is supported by adequate and well-controlled studies in adults, as well as additional pharmacokinetic data in pediatric patients and an analysis of the published literature (see <a href="#b3783bf3-1821-48be-a9ec-bc91c5af73cc">CLINICAL PHARMACOLOGY: Pediatrics</a> and <a href="#bdf7c8b5-8dd7-4b1a-8780-cdca44ba33a6">DOSAGE AND ADMINISTRATION: Pediatric Use</a>).</p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Safety and effectiveness in pediatric patients for the treatment of pathological hypersecretory conditions or the maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> have not been established.</p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Safety and effectiveness in neonates (less than 1 month of age) have not been established (see <a href="#bd54b83d-5e81-4ae9-b979-3d3d363d768b">CLINICAL PHARMACOLOGY: Pediatrics</a>).</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="bc2a9e3a-224c-4c18-8af1-dc5f14c7d55f"></a><a name="section-5.8"></a><p></p>
<h2><span class="Bold Italics">Geriatric Use
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Of the total number of subjects enrolled in US and foreign controlled clinical trials of oral formulations of ranitidine, for which there were subgroup analyses, 4,197 were 65 and over, while 899 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> This drug is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, caution should be exercised in dose selection, and it may be useful to monitor renal function (see <a href="#ba90d3f0-afc2-4d7d-9e09-9de10cee77c6">CLINICAL PHARMACOLOGY:</a><a href="#b811b210-4b96-4ff1-ba7a-f1504af17ec2">Pharmacokinetics: Geriatrics</a> and <a href="#b855e588-bbc3-47d1-a123-130778c5e956">DOSAGE AND ADMINISTRATION: Dosage Adjustment for Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a>).</p></dd>
</dl>  </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="b250d5b5-f7ec-4531-9a05-6ccc0b8105ce"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS
</span></h1>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The following have been reported as events in clinical trials or in the routine management of patients treated with ranitidine. The relationship to therapy with ranitidine has been unclear in many cases. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, sometimes severe, seems to be related to administration of ranitidine.</p></dd>
</dl>  </dd>
</dl>
<div class="Section">
<a name="section-6.1"></a><p></p>
<h2><span class="Bold Italics">Central Nervous System
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Rarely, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. Rare cases of reversible <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> have been reported, predominantly in severely ill elderly patients. Rare cases of reversible <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> suggestive of a change in accommodation have been reported. Rare reports of reversible involuntary motor disturbances have been received.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold Italics">Cardiovascular
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> As with other H<span class="Sub">2</span>-blockers, rare reports of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> such as <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, and premature ventricular beats.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-6.3"></a><p></p>
<h2><span class="Bold Italics">Gastrointestinal
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and rare reports of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-6.4"></a><p></p>
<h2><span class="Bold Italics">Hepatic
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> There have been occasional reports of hepatocellular, cholestatic, or mixed <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. In such circumstances, ranitidine should be immediately discontinued. These events are usually reversible, but in rare circumstances <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has occurred. Rare cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have also been reported. In normal volunteers, SGPT values were increased to at least twice the pretreatment levels in 6 of 12 subjects receiving 100 mg intravenously 4 times daily for 7 days, and in 4 of 24 subjects receiving 50 mg intravenously 4 times daily for 5 days.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-6.5"></a><p></p>
<h2><span class="Bold Italics">Musculoskeletal
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Rare reports of <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-6.6"></a><p></p>
<h2><span class="Bold Italics">Hematologic
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Blood count changes (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) have occurred in a few patients. These were usually reversible. Rare cases of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, sometimes with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow hypoplasia</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> and exceedingly rare cases of acquired immune <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> have been reported.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-6.7"></a><p></p>
<h2><span class="Bold Italics">Endocrine
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Controlled studies in animals and man have shown no stimulation of any pituitary hormone by ranitidine and no antiandrogenic activity, and cimetidine-induced <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> in hypersecretory patients have resolved when ranitidine has been substituted. However, occasional cases of <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, and <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span> have been reported in male patients receiving ranitidine, but the incidence did not differ from that in the general population.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-6.8"></a><p></p>
<h2><span class="Bold Italics">Integumentary
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, including rare cases of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>. Rare cases of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-6.9"></a><p></p>
<h2><span class="Bold Italics">Respiratory
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> A large epidemiological study suggested an increased risk of developing <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in current users of histamine-2–receptor antagonists (H2RAs) compared to patients who had stopped H<span class="Sub">2</span>RA treatment, with an observed adjusted relative risk of 1.63 (95% CI,1.07–2.48). However, a causal relationship between use of H<span class="Sub">2</span>RAs and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> has not been established.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-6.10"></a><p></p>
<h2><span class="Bold Italics">Other
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>), <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">acute interstitial nephritis</span>, and small increases in serum creatinine.</p></dd>
</dl>  </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-7"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> There has been limited experience with overdosage. Reported acute ingestions of up to 18 g orally have been associated with transient adverse effects similar to those encountered in normal clinical experience (see <a href="#b250d5b5-f7ec-4531-9a05-6ccc0b8105ce">ADVERSE REACTIONS</a>). In addition, abnormalities of gait and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> have been reported.</p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> When overdosage occurs, the usual measures to remove unabsorbed material from the gastrointestinal tract, clinical monitoring, and supportive therapy should be employed.</p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Studies in dogs receiving dosages of ranitidine in excess of 225 mg/kg/day have shown muscular <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and rapid respiration. Single oral doses of 1,000 mg/kg in mice and rats were not lethal. Intravenous LD<span class="Sub">50</span> values in mice and rats were 77 and 83 mg/kg, respectively.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="bfee2f1d-b920-415c-8876-b11b95d61ccb"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<div class="Section">
<a name="section-8.1"></a><p></p>
<h2><span class="Bold Italics">Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span>
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The current recommended adult oral dosage of ranitidine oral solution USP for <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of ranitidine) twice daily. An alternative dosage of 300 mg or 20 mL of oral solution (4 teaspoonfuls of oral solution equivalent to 300 mg of ranitidine) once daily after the evening meal or at bedtime can be used for patients in whom dosing convenience is important. The advantages of one treatment regimen compared to the other in a particular patient population have yet to be demonstrated (see <a href="#b082a525-848d-4511-9d4e-0a33b3f0442c">Clinical Trials: Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></a>). Smaller doses have been shown to be equally effective in inhibiting gastric acid secretion in US studies, and several foreign trials have shown that 100 mg twice daily is as effective as the 150-mg dose.</p></dd>
<dt></dt>
<dd><p class="First"> Antacid should be given as needed for relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (see <a href="#b34ce51a-1d7b-4222-bf4b-abf3a896fb87">CLINICAL PHARMACOLOGY: Pharmacokinetics</a>).</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold Italics">Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span>
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of ranitidine) at bedtime.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-8.3"></a><p></p>
<h2><span class="Bold Italics">Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome)
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of ranitidine) twice a day. In some patients it may be necessary to administer ranitidine 150-mg doses more frequently. Dosages should be adjusted to individual patient needs, and should continue as long as clinically indicated. Dosages up to 6 g/day have been employed in patients with severe disease.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-8.4"></a><p></p>
<h2><span class="Bold Italics">Benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span>
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of ranitidine) twice daily.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-8.5"></a><p></p>
<h2><span class="Bold Italics">Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcers</span>
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of ranitidine) at bedtime.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-8.6"></a><p></p>
<h2><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of ranitidine) twice daily.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-8.7"></a><p></p>
<h2><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span>
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of ranitidine) 4 times daily.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="section-8.8"></a><p></p>
<h2><span class="Bold Italics">Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span>
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of ranitidine) twice daily.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="bdf7c8b5-8dd7-4b1a-8780-cdca44ba33a6"></a><a name="section-8.9"></a><p></p>
<h2><span class="Bold Italics">Pediatric Use
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> The safety and effectiveness of ranitidine oral solution USP have been established in the age-group of 1 month to 16 years. There is insufficient information about the pharmacokinetics of ranitidine oral solution USP in neonatal patients (less than 1 month of age) to make dosing recommendations.</p></dd>
<dt></dt>
<dd><p class="First"> The following 3 subsections provide dosing information for each of the pediatric indications.</p></dd>
<dt></dt>
<dd><p class="First"> Treatment of Duodenal and <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcers</span></p></dd>
<dt></dt>
<dd><p class="First"> The recommended oral dose for the treatment of active duodenal and <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> is 2 to 4 mg/kg twice daily to a maximum of 300 mg/day. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients.</p></dd>
<dt></dt>
<dd><p class="First"> Maintenance of Healing of Duodenal and <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcers</span></p></dd>
<dt></dt>
<dd><p class="First"> The recommended oral dose for the maintenance of healing of duodenal and <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> is 2 to 4 mg/kg once daily to a maximum of 150 mg/day. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients.</p></dd>
<dt></dt>
<dd><p class="First"> Treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> and <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></p></dd>
<dt></dt>
<dd><p class="First"> Although limited data exist for these conditions in pediatric patients, published literature supports a dosage of 5 to 10 mg/kg/day, usually given as 2 divided doses.</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section">
<a name="b855e588-bbc3-47d1-a123-130778c5e956"></a><a name="section-8.10"></a><p></p>
<h2><span class="Bold Italics">Dosage Adjustment for Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>
</span></h2>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> On the basis of experience with a group of subjects with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> treated with ranitidine oral solution USP, the recommended dosage in patients with a creatinine clearance &lt;50 mL/min is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of ranitidine) every 24 hours. Should the patient's condition require, the frequency of dosing may be increased to every 12 hours or even further with caution. Hemodialysis reduces the level of circulating ranitidine. Ideally, the dosing schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis.</p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Elderly patients are more likely to have decreased renal function, therefore caution should be exercised in dose selection, and it may be useful to monitor renal function (see <a href="#b811b210-4b96-4ff1-ba7a-f1504af17ec2">CLINICAL</a><a href="#b811b210-4b96-4ff1-ba7a-f1504af17ec2">PHARMACOLOGY: Pharmacokinetics: Geriatrics</a> and <a href="#bc2a9e3a-224c-4c18-8af1-dc5f14c7d55f">PRECAUTIONS: Geriatric Use</a>).</p></dd>
</dl>  </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED
</span></h1>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Ranitidine oral solution USP, a clear <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow liquid, natural &amp; artificial mint flavor contains 16.8 mg of ranitidine HCl equivalent to 15 mg of ranitidine per mL (75 mg/5 mL)</p></dd>
<dt></dt>
<dd><p class="First"> Bottles of 16 fluid ounces                                                                    NDC 23155-291-51</p></dd>
<dt></dt>
<dd><p class="First"> Store between 4° and 25°C (39° and 77°F). Do not freeze. Dispense in tight, light-resistant containers as defined in the USP/NF.</p></dd>
<dt></dt>
<dd><p class="First"> Rx Only</p></dd>
<dt></dt>
<dd><p class="First"> Manufactured for:</p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"><span class="Bold">Heritage Pharmaceuticals Inc.</span><span class="Bold"><br></span>Eatontown, NJ 07724<br>1.866.901.DRUG (3784)</p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> R 06/14</p></dd>
</dl>  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-10"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"> Ranitidine oral solution USP</p></dd>
<dt></dt>
<dd><p class="First"> 15 mg of ranitidine per mL</p></dd>
</dl>  </dd>
</dl>
<dl>
<dt> </dt>
<dd>
<dl>
<dt></dt>
<dd><p class="First"><img alt="6bf5f8d4-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd7a6355-0341-4bce-a942-2a8bba3fb669&amp;name=6bf5f8d4-figure-02.jpg"></p></dd>
</dl>  </dd>
</dl>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RANITIDINE 		
					</strong><br><span class="contentTableReg">ranitidine syrup</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:23155-291</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RANITIDINE HYDROCHLORIDE</strong> (RANITIDINE) </td>
<td class="formItem">RANITIDINE</td>
<td class="formItem">15 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MINT</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">MINT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:23155-291-51</td>
<td class="formItem">480 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090102</td>
<td class="formItem">07/15/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Heritage Pharmaceuticals Inc.
							(780779901)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bio-Pharm, Inc.</td>
<td class="formItem"></td>
<td class="formItem">801652546</td>
<td class="formItem">MANUFACTURE(23155-291)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6bf5f8d4-1a53-499c-8ef8-8b6c7383bc62</div>
<div>Set id: dd7a6355-0341-4bce-a942-2a8bba3fb669</div>
<div>Version: 3</div>
<div>Effective Time: 20140814</div>
</div>
</div> <div class="DistributorName">Heritage Pharmaceuticals Inc.</div></p>
</body></html>
